Business Description
Morphic Holding Inc
NAICS : 325412
SIC : 2834
ISIN : US61775R1059
Description
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 200.78 | |||||
| Equity-to-Asset | 0.97 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -79.9 | |||||
| 3-Year EBITDA Growth Rate | -40.7 | |||||
| 3-Year EPS without NRI Growth Rate | -34.7 | |||||
| 3-Year FCF Growth Rate | -20.8 | |||||
| 3-Year Book Growth Rate | 45.7 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.76 | |||||
| 9-Day RSI | 41.13 | |||||
| 14-Day RSI | 39.32 | |||||
| 6-1 Month Momentum % | 64.14 | |||||
| 12-1 Month Momentum % | -33.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 38.17 | |||||
| Quick Ratio | 38.17 | |||||
| Cash Ratio | 37.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.8 | |||||
| Shareholder Yield % | -24.43 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -24685.6 | |||||
| ROE % | -24.89 | |||||
| ROA % | -24.14 | |||||
| ROIC % | -2462.02 | |||||
| ROC (Joel Greenblatt) % | -3211.55 | |||||
| ROCE % | -29.74 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2388.96 | |||||
| PB Ratio | 2.17 | |||||
| Price-to-Tangible-Book | 2.17 | |||||
| EV-to-EBIT | -3.86 | |||||
| EV-to-EBITDA | -3.88 | |||||
| EV-to-Revenue | 1431.16 | |||||
| EV-to-Forward-Revenue | 745.63 | |||||
| EV-to-FCF | -5.8 | |||||
| Price-to-Net-Current-Asset-Value | 2.19 | |||||
| Price-to-Net-Cash | 2.25 | |||||
| Earnings Yield (Greenblatt) % | -25.91 | |||||
| FCF Yield % | -8.94 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers